In a trial with 120 advanced bile‑duct cancer patients, adding a traditional Chinese medicine (Xihuang pill) to a combo of an immune‑checkpoint drug (tislelizumab) and the peptide thymosin‑alpha‑1 improved tumor response and lowered side‑effects compared to the drugs alone, but it didn’t significantly extend one‑year survival.
Costantini. Claudio C; van de Veerdonk. Frank L FL; Romani. Luigina L
The paper explains that COVID‑19 can mess up the immune system, making people more likely to get a dangerous lung fungus called aspergillosis. It says fixing the immune imbalance might lower that risk, but it doesn’t give any concrete steps or data on using thymosin‑alpha‑1.
Costantini. Claudio C; Puccetti. Matteo M; Pariano. Marilena M; Renga. Giorgia G; Stincardini. Claud...
The paper reviews how inflammation drives lung problems in cystic fibrosis and looks at drugs that might calm the immune system without making infections worse. It stresses that any anti‑inflammatory approach should be very selective, targeting the body’s own broken regulation pathways, but it doesn’t give specific dosing or protocols for people to try on their own.
Xi. Yang Y; Jingying. Dai D; Chenglong. Li L; Hong. Zheng Z; Rong. Zhang Z; Xiaodong. Wang W; Chunse...
The study gave leukemia patients a mix of two epigenetic drugs and the peptide thymosin‑alpha‑1 and found it was safe and helped many patients’ cancers go into remission, while also shifting their immune cells toward a Th1‑dominant profile. However, this was done in very sick patients after a stem‑cell transplant, not in healthy people, so the results don’t translate into a simple at‑home protocol.
A study looked at people with advanced skin cancer who got a peptide called thymosin‑alpha‑1 before receiving an immune‑boosting drug (ipilimumab). Those who got the peptide first lived much longer than those who didn’t, hinting the two might work better together. However, this was done in sick cancer patients under medical care, not healthy individuals.
The study shows that the peptide thymosin‑alpha‑1 can kill breast cancer cells in a dish by boosting a tumor‑suppressor protein called PTEN, which then shuts down a growth‑promoting pathway (PI3K/Akt/mTOR). This effect only works well in cells that have functional PTEN, and the peptide triggers the cells' internal suicide mechanisms.
The study shows that thymosin‑alpha‑1, a peptide some people think might help cystic fibrosis, does not improve the faulty CFTR protein or boost chloride channel activity in airway cells, though it might still reduce inflammation.
A study of sick patients with sepsis found that adding the immune‑boosting peptide thymosin‑alpha‑1 to the drug ulinastatin lowered death rates and helped some clinical measures, but the research was done in critically ill hospital patients, not healthy individuals looking to improve longevity or performance.
A study combining two drugs, ulinastatin and thymosin‑alpha‑1, showed that seriously ill sepsis patients had lower death rates, less inflammation, and spent fewer days on a ventilator compared to a placebo. However, these results come from hospital‑based trials on very sick patients, not from healthy or performance‑focused individuals.
Yang. Na N; Ke. Lu L; Tong. Zhihui Z; Li. Weiqin W
A recent review looked at using the immune‑boosting peptide thymosin‑alpha‑1 to stop infections in people with severe acute pancreatitis, a serious condition where infection often kills patients. Early small studies suggest it might help, but the evidence is still weak and larger trials are needed.
The study used high‑resolution mass spectrometry to map many natural variants and chemical modifications of thymosin peptides in tissues and fluids, but it didn’t test any health effects or dosing strategies.
Scientists added a short tag (RGDR) to the immune‑boosting peptide thymosin‑alpha‑1, creating a new version that homes in on tumors better. In mouse melanoma tests, this modified peptide slowed tumor growth more than the original, while still keeping similar immune‑system effects. The study is early‑stage and focused on cancer treatment, not everyday health hacks.
In a lab study using blood cells from kids with leukemia, adding the peptide thymosin‑alpha‑1 helped the immune cells called dendritic cells look and act more mature and boosted their ability to direct killer T‑cells against cancer cells.
This study looked at whether two drugs, ulinastatin and thymosin‑alpha‑1, help people with severe sepsis survive. It found that using both together lowered death rates at 28 and 90 days, while thymosin‑alpha‑1 alone only helped at 28 days. The evidence isn’t strong enough to change everyday health routines, and the drugs are only for serious hospital cases.
This abstract describes a planned clinical trial that will test whether giving the peptide thymosin‑alpha‑1 to patients after emergency surgery for a torn aorta can lower organ damage by calming the immune system. No results are available yet, so we don’t know if it works.
Scientists made a friendly bacteria that makes a pig virus protein and gave it to pigs by mouth. Adding the immune‑boosting peptide thymosin‑alpha‑1 made the pigs’ immune response stronger than the bacteria alone. This shows the peptide can act as a vaccine helper, but the work was done in pigs, not people, and uses genetic engineering that isn’t practical for everyday use.
Scientists made a new protein that mixes thymosin‑alpha‑1 with another peptide and used it to boost a flu vaccine in chickens. It helped the birds make more antibodies and fight off the virus better, but the work was done in birds, not people.
A small, low‑quality study tested thymosin‑alpha‑1 on knocked‑out front teeth and saw a hint it might help the gums and keep the tooth alive, but the evidence is weak and not reliable for everyday use.
Aslam. Muhammad Shahbaz MS; Gull. Iram I; Mahmood. Malik Siddique MS; Iqbal. Muhammad Mudassir MM; A...
Researchers made a combined protein that joins interferon‑alpha2 and thymosin‑alpha1, showed they could produce it in bacteria at high levels, and found it kills cancer cells better than interferon alone, but the work is all lab‑based and doesn’t give any dosing or safety info for people to use.
Scientists built a pig interferon‑alpha1 and thymosin‑alpha1 fusion protein in bacteria and showed it works in lab tests, but the work is purely in vitro and uses animal proteins, so it doesn’t give any direct guidance for people who want to use thymosin‑alpha1 for health or performance.